Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 23320 | 4.61 |
09:36 ET | 800 | 4.68 |
09:38 ET | 1684 | 4.69 |
09:39 ET | 3587 | 4.69 |
09:41 ET | 2895 | 4.66 |
09:45 ET | 1408 | 4.66 |
09:48 ET | 12160 | 4.665 |
09:50 ET | 2383 | 4.6599 |
09:52 ET | 200 | 4.66 |
09:54 ET | 2163 | 4.65 |
09:56 ET | 725 | 4.665 |
09:57 ET | 1600 | 4.695 |
09:59 ET | 1400 | 4.71 |
10:01 ET | 1841 | 4.71 |
10:03 ET | 1705 | 4.7 |
10:06 ET | 13741 | 4.76 |
10:08 ET | 15073 | 4.83 |
10:10 ET | 7783 | 4.81 |
10:12 ET | 22063 | 4.87 |
10:14 ET | 22676 | 4.9 |
10:15 ET | 22863 | 4.8999 |
10:17 ET | 13592 | 4.94 |
10:19 ET | 21882 | 4.955 |
10:21 ET | 14350 | 4.93 |
10:24 ET | 20143 | 5.01 |
10:26 ET | 24387 | 5.03 |
10:28 ET | 32114 | 5.06 |
10:30 ET | 6736 | 5.01 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 3.3B | -3.3x | --- |
Biohaven Ltd | 3.1B | -6.2x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Iovance Biotherapeutics Inc | 3.1B | -6.1x | --- |
Xenon Pharmaceuticals Inc | 3.1B | -15.4x | --- |
Apogee Therapeutics Inc | 3.0B | -30.9x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.3B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.26 |
EPS | $-1.54 |
Book Value | $0.11 |
P/E Ratio | -3.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.